Measuring disease activity in COPD: is clinically important deterioration the answer?
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1465-993X
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Measuring disease activity in COPD: is clinically important deterioration the answer? ; volume:21 ; number:1 ; day:2 ; month:6 ; year:2020 ; pages:1-13 ; date:12.2020
Respiratory research ; 21, Heft 1 (2.6.2020), 1-13, 12.2020
- Creator
-
Singh, Dave
Criner, Gerard J.
Naya, Ian
Jones, Paul W.
Tombs, Lee
Lipson, David A.
Han, MeiLan K.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12931-020-01387-z
- URN
-
urn:nbn:de:101:1-2020080318585112569435
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:47 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Singh, Dave
- Criner, Gerard J.
- Naya, Ian
- Jones, Paul W.
- Tombs, Lee
- Lipson, David A.
- Han, MeiLan K.
- SpringerLink (Online service)
Other Objects (12)
Correction to: Measuring disease activity in COPD: is clinically important deterioration the answer?
Composite endpoints in COPD: clinically important deterioration in the UPLIFT trial
Long-term outcomes following first short-term clinically important deterioration in COPD
Indacaterol/glycopyrronium versus salmeterol/fluticasone in the prevention of clinically important deterioration in COPD: results from the FLAME study
One‐year clinically important deterioration and long‐term clinical course in Japanese patients with COPD: a multicenter observational cohort study
Reduction in clinically important deterioration in chronic obstructive pulmonary disease with aclidinium/formoterol
Health status measurement in COPD: the minimal clinically important difference of the clinical COPD questionnaire
Preventing Clinically Important Deterioration of COPD with Addition of Umeclidinium to Inhaled Corticosteroid/Long-Acting β2-Agonist Therapy: An Integrated Post Hoc Analysis
Tiotropium/Olodaterol Delays Clinically Important Deterioration Compared with Tiotropium Monotherapy in Patients with Early COPD: a Post Hoc Analysis of the TONADO® Trials
Health status instruments for patients with COPD in pulmonary rehabilitation: defining a minimal clinically important difference
Identifying clinically important COPD sub-types using data-driven approaches in primary care population based electronic health records
Reduced risk of clinically important deteriorations by ICS in COPD is eosinophil dependent: a pooled post-hoc analysis
Correction to: Measuring disease activity in COPD: is clinically important deterioration the answer?
Composite endpoints in COPD: clinically important deterioration in the UPLIFT trial
Long-term outcomes following first short-term clinically important deterioration in COPD
Indacaterol/glycopyrronium versus salmeterol/fluticasone in the prevention of clinically important deterioration in COPD: results from the FLAME study
One‐year clinically important deterioration and long‐term clinical course in Japanese patients with COPD: a multicenter observational cohort study
Reduction in clinically important deterioration in chronic obstructive pulmonary disease with aclidinium/formoterol
Health status measurement in COPD: the minimal clinically important difference of the clinical COPD questionnaire
Preventing Clinically Important Deterioration of COPD with Addition of Umeclidinium to Inhaled Corticosteroid/Long-Acting β2-Agonist Therapy: An Integrated Post Hoc Analysis
Tiotropium/Olodaterol Delays Clinically Important Deterioration Compared with Tiotropium Monotherapy in Patients with Early COPD: a Post Hoc Analysis of the TONADO® Trials
Health status instruments for patients with COPD in pulmonary rehabilitation: defining a minimal clinically important difference
Identifying clinically important COPD sub-types using data-driven approaches in primary care population based electronic health records
Reduced risk of clinically important deteriorations by ICS in COPD is eosinophil dependent: a pooled post-hoc analysis
Correction to: Measuring disease activity in COPD: is clinically important deterioration the answer?
Composite endpoints in COPD: clinically important deterioration in the UPLIFT trial
Long-term outcomes following first short-term clinically important deterioration in COPD
Indacaterol/glycopyrronium versus salmeterol/fluticasone in the prevention of clinically important deterioration in COPD: results from the FLAME study
One‐year clinically important deterioration and long‐term clinical course in Japanese patients with COPD: a multicenter observational cohort study
Reduction in clinically important deterioration in chronic obstructive pulmonary disease with aclidinium/formoterol
Health status measurement in COPD: the minimal clinically important difference of the clinical COPD questionnaire
Preventing Clinically Important Deterioration of COPD with Addition of Umeclidinium to Inhaled Corticosteroid/Long-Acting β2-Agonist Therapy: An Integrated Post Hoc Analysis
Tiotropium/Olodaterol Delays Clinically Important Deterioration Compared with Tiotropium Monotherapy in Patients with Early COPD: a Post Hoc Analysis of the TONADO® Trials
Health status instruments for patients with COPD in pulmonary rehabilitation: defining a minimal clinically important difference
Identifying clinically important COPD sub-types using data-driven approaches in primary care population based electronic health records